Filtered By:
Source: Neurology
Condition: Bleeding

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies (S56.008)
Conclusions:There is no apparent increased risk of bleeding complications in patients on antithrombotics following IM onabotA treatment; nonetheless, careful observation of the injection site and patient education of the potential for bleeding complications remain warranted.Study Supported by: Allergan plc, Dublin, IrelandDisclosure: Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan. Dr. James has received personal compensation for activities with Allergan and Chase Pharmaceuticals as an employee. Dr. Liu has received per...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Dimitrova, R., James, L., Liu, C., Orejudos, A., Yushmanova, I., Brin, M. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research

Teaching NeuroImages: Swirl sign and spot sign in intraparenchymal hematoma
A 10-year-old-girl was admitted with headache and vomiting. Nonenhanced CT showed hyperdense intraparenchymal hematoma with a hypodense area, consistent with swirl sign, a classic sign of active bleeding (figure 1).
Source: Neurology - October 30, 2016 Category: Neurology Authors: Wagemans, B. A. J. M., Klinkenberg, S., Postma, A. A. Tags: CT, Prognosis, Pediatric stroke; see Cerebrovascular Disease/ Childhood stroke, Intracerebral hemorrhage RESIDENT AND FELLOW SECTION Source Type: research

Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies
Conclusions: The incidence of symptomatic hemorrhage or rehemorrhage is higher in brainstem lesions. First symptomatic hemorrhage increases the chance of symptomatic rehemorrhage, which decreases after 2 years.
Source: Neurology - May 22, 2016 Category: Neurology Authors: Taslimi, S., Modabbernia, A., Amin-Hanjani, S., Barker, F. G., Macdonald, R. L. Tags: Other cerebrovascular disease/ Stroke, All Cerebrovascular disease/Stroke, Incidence studies, Natural history studies (prognosis), Intracerebral hemorrhage ARTICLE Source Type: research

Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance
Post hoc analyses of data from randomized controlled trials can generate useful hypotheses, but need to be considered exploratory. When conducted, such evaluations should adhere to specified criteria and test for a treatment by subgroup interaction for the trial's primary endpoint.1 The best way to proceed if unexpected but potentially important outcomes occur is less clear. Concern that treatment with HMG-CoA reductase inhibitors (i.e., statins) might increase the risk of poststroke intracerebral hemorrhage (ICH) arose from an unanticipated observation in the Stroke Prevention with Aggressive Reduction in Cholesterol Leve...
Source: Neurology - April 24, 2016 Category: Neurology Authors: Goldstein, L. B., Nederkoorn, P. J. Tags: All Cerebrovascular disease/Stroke, Intracerebral hemorrhage EDITORIALS Source Type: research

Is Eptifibatide a Viable and Safe Option as Stand-Alone Therapy for Acute Ischemic Stroke Patients? (P2.278)
Conclusion: In patients who are not candidates for IV tPA eptifibatide may be a safe and efficacious alternative. None of the patients who were started on eptifibatide had bleeding complications and they had a statistically significant improvement in their level of disability and stroke severity at discharge. To better evaluate the efficacy of eptifibatide, a larger, prospective study should be initiatedDisclosure: Dr. Korya has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclos...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Daniel, J., Samaan, M., Panezai, S., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Use of Cardiac Stents to Reperfuse the Brain (P2.280)
CONCLUSIONS: Cardiac stents are easily deployed and associated with few complications. Outcomes were favorable. A larger, prospective trial is needed to evaluate and compare cardiac stents with the currently used stents used for cerebrovascular ischemic disease.Disclosure: Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Nizam has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Moussavi, M., Mehta, S., Korya, D., Brar, J., Khan, N., Nizam, S., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Alcoholism and In-Hospital Mortality among Hemorrhagic Stroke Patients in Puerto Rico (P1.263)
Conclusions: The adjusted OR of 3.18 suggests a positive association and in-patient hemorrhagic stroke mortality. However the small sample size and low power limit the ability to delineate a clear statistical association, thereby warranting further study into this subject matter as alcoholism is a modifiable risk factor and early interventions may lower hemorrhagic stroke mortality in this population.Disclosure: Dr. Smirnoff has nothing to disclose. Dr. Moses has nothing to disclose. Dr. Zevallos has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Smirnoff, L., Moses, A., Zevallos, J. C. Tags: Cerebrovascular Disease: Health Disparities Source Type: research

Outcomes After Thrombolysis for Acute Ischemic Stroke for Adults 65 and Older: A Nationwide Inpatient Sample Analysis (P1.267)
Conclusions: This analysis suggests clinical outcomes for older adult patients who receive IVtPA for AIS are worse compared to those who do not. Nuanced investigation must be done to confirm findings, and to address potential changes in current treatment strategies for this population.Disclosure: Dr. Song has nothing to disclose. Dr. Ouyang has nothing to disclose. Dr. Cherian has nothing to disclose. Dr. Cutting has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Conners has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Song, S., Ouyang, B., Cherian, L., Cutting, S., Lee, V., Conners, J. Tags: Cerebrovascular Disease: Health Disparities Source Type: research

The History of Aspirin: from Willow Bark to Thomas Edison in the 20th Century (P2.391)
CONCLUSION: The evolution of Aspirin in the 20th century aligned with historical events leading to its place as one of the most widely used drugs in history.Disclosure: Dr. Southerland has received personal compensation in an editorial capacity for Neurology podcast.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Southerland, A. Tags: History of Neurology Source Type: research

Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologists and Haematologists in a Canadian Survey (P6.007)
Conclusions: In this cohort, there are differences between neurologists and hematologists with regards to initial choice of anticoagulant. It is possible that more complex presenting cases of CVT with concurrent venous infarction, hemorrhage or seizure may present to neurologists as compared to hematologists. Thus, an initial preference for UFH may reflect a desire for a reversible agent with a short half-life in the event of bleeding complications in an unstable patient. Our study is limited by response bias, though our response rate of 28[percnt] is comparable to other contemporary web-based physician surveys. The majori...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alshimemeri, S., Camden, M.-C., Lui, G., Lee, A., Field, T. Tags: Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Source Type: research

Gastrointestinal Bleeding in Acute Ischemic Stroke: Recent Trend and Predictors. (P6.040)
CONCLUSIONS:GIB is relatively known complication in setting of AIS. Decremental trend in recent years does not have any association with chemical or mechanical thrombolysis but instead was predicted by chronic altered metabolic states like NSAID use, alcohol abuse and Atrial fibrillation.Disclosure: Dr. Shah has nothing to disclose. Dr. Patel has nothing to disclose. Dr. Patel has nothing to disclose. Dr. Hazra has nothing to disclose. Dr. Lunagariya has nothing to disclose. Dr. Jani has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Kassab has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Qure...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Shah, H., Patel, A., Patel, U., Hazra, A., Lunagariya, A., Mishra, P., Jani, V., Mehta, S., Kassab, M., Hussain, S., Qureshi, A. Tags: In-Hospital Stroke and Stroke Complications Source Type: research

Intra-Arterial Stem Cell Therapy for a Persistent Vegetative State Patient: A DTI Analysis of Recovery (P6.066)
Conclusion Assessing minor neurological improvements in this patient remains challenging but advances in neuroimaging as an evaluating tool helps to detect those changes. Future assessments and imaging will be performed to better clarify the findings mentioned above.Disclosure: Dr. Ramdas has nothing to disclose. Dr. Guada has nothing to disclose. Dr. Pafford has nothing to disclose. Dr. Haussen has nothing to disclose. Dr. Pattany has nothing to disclose. Dr. Yavagal has received personal compensation for activities with Covidien/evV3 as a consultant and Steering Committee Member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Ramdas, K., Guada, L., Pafford, R., Haussen, D., Pattany, P., Yavagal, D. Tags: Cerebrovascular Disease: Miscellaneous Interventions Source Type: research

Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologists and Haematologists in a Canadian Survey (I2.010)
Conclusions: In this cohort, there are differences between neurologists and hematologists with regards to initial choice of anticoagulant. It is possible that more complex presenting cases of CVT with concurrent venous infarction, hemorrhage or seizure may present to neurologists as compared to hematologists. Thus, an initial preference for UFH may reflect a desire for a reversible agent with a short half-life in the event of bleeding complications in an unstable patient. Our study is limited by response bias, though our response rate of 28[percnt] is comparable to other contemporary web-based physician surveys. The majori...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alshimemeri, S., Camden, M.-C., Lui, G., Lee, A., Field, T. Tags: Stroke in the Elderly and Young: Challenges for the Next Decade Poster Presentations Source Type: research

How temporal evolution of intracranial collaterals in acute stroke affects clinical outcomes
Conclusions: Not all collateral recruitment is beneficial; delayed collateral recruitment may be different from early recruitment and can result in worse outcomes and higher mortality. Prethrombolysis collateral status and recanalization are determinants of how intracranial collateral evolution affects functional outcomes.
Source: Neurology - February 1, 2016 Category: Neurology Authors: Yeo, L. L. L., Paliwal, P., Low, A. F., Tay, E. L. W., Gopinathan, A., Nadarajah, M., Ting, E., Venketasubramanian, N., Seet, R. C. S., Ahmad, A., Chan, B. P. L., Teoh, H. L., Soon, D., Rathakrishnan, R., Sharma, V. K. Tags: CT, All Cerebrovascular disease/Stroke, Infarction ARTICLE Source Type: research

Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE
Conclusions: The results indicated higher rate of recurrent stroke in minor stroke or high-risk TIA patients with ICAS than in those without. However, there was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial. Classification of evidence: This study provides Class II evidence that for patients with acute minor stroke or TIA with and without ICAS identified by MRA, clopidogrel plus aspirin is not significantly different than aspirin alone in preventing recurrent stroke.
Source: Neurology - September 28, 2015 Category: Neurology Authors: Liu, L., Wong, K. S. L., Leng, X., Pu, Y., Wang, Y., Jing, J., Zou, X., Pan, Y., Wang, A., Meng, X., Wang, C., Zhao, X., Soo, Y., Johnston, S. C., Wang, Y., For the CHANCE Investigators Tags: ARTICLE Source Type: research